Hemab Therapeutics Holdings, Inc. (COAG) Reports Sutacimig PT Shortened Over 50% After One Dose
Hemab Therapeutics (COAG) reported that sutacimig reduced prothrombin time by over 50% in two patients with severe Factor VII deficiency after one dose. One patient showed a 5x increase in endogenous FVII(a) by Day 22. HMB-003 reduced severe bleeding days in a monkey model. Further data is expected in mid-2027.
How this was made

The 30-second read
Why it matters
The >50% shortening of prothrombin time suggests the drug engages its target, potentially accelerating the path to later‑stage trials and partnership interest.
Market read
First‑report clinical data for a micro‑cap biotech; could spark short‑term price movement and attract speculative interest.
What to watch
Regulatory timeline and funding needs for Phase 1/2 trials could constrain upside.
Background
Hemab Therapeutics (COAG) is a clinical‑stage biotech focused on rare coagulation disorders. The company recently announced its first human dose data for sutacimig.
Ticker impact
Hemab Therapeutics reported that two severe Factor VII deficiency patients showed >50% prothrombin time shortening after a single sutacimig dose, indicating early clinical efficacy.
potential upside as the market prices in the encouraging efficacy signal
Early human data and preclinical results are novel and material for a micro‑cap biotech, but further trials are needed before a decisive move.
Market effects
May boost interest in rare‑disease gene‑therapy and coagulation‑disorder pipelines.
Limited to US biotech investors; no broad regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
Early data could be over‑hyped; small sample size and lack of control may limit price reaction.
Key entities
- companyHemab Therapeutics Holdings, Inc.
US‑listed biotech developing sutacimig for Factor VII deficiency.


